JP2005519091A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519091A5
JP2005519091A5 JP2003572444A JP2003572444A JP2005519091A5 JP 2005519091 A5 JP2005519091 A5 JP 2005519091A5 JP 2003572444 A JP2003572444 A JP 2003572444A JP 2003572444 A JP2003572444 A JP 2003572444A JP 2005519091 A5 JP2005519091 A5 JP 2005519091A5
Authority
JP
Japan
Prior art keywords
use according
cancer
herpesvirus
subject
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003572444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/006519 external-priority patent/WO2003073918A2/en
Publication of JP2005519091A publication Critical patent/JP2005519091A/ja
Publication of JP2005519091A5 publication Critical patent/JP2005519091A5/ja
Pending legal-status Critical Current

Links

JP2003572444A 2002-03-01 2003-03-03 癌の再発及び転移の予防 Pending JP2005519091A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36113202P 2002-03-01 2002-03-01
PCT/US2003/006519 WO2003073918A2 (en) 2002-03-01 2003-03-03 Prevention of recurrence and metastasis of cancer

Publications (2)

Publication Number Publication Date
JP2005519091A JP2005519091A (ja) 2005-06-30
JP2005519091A5 true JP2005519091A5 (cg-RX-API-DMAC7.html) 2006-04-20

Family

ID=27789076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003572444A Pending JP2005519091A (ja) 2002-03-01 2003-03-03 癌の再発及び転移の予防

Country Status (6)

Country Link
US (1) US20050255085A1 (cg-RX-API-DMAC7.html)
EP (1) EP1487983A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005519091A (cg-RX-API-DMAC7.html)
AU (1) AU2003216502B2 (cg-RX-API-DMAC7.html)
CA (1) CA2476724A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003073918A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
JP2005336094A (ja) * 2004-05-26 2005-12-08 Akikimi Nakao 変異単純ヘルペスウイルスからなる転移性乳癌および再発性乳癌の治療剤
US8986672B2 (en) * 2005-06-23 2015-03-24 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
DK3184641T3 (da) 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
ES2796488T3 (es) * 2016-04-08 2020-11-27 Krystal Biotech Inc Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel
EP3426272A4 (en) 2016-04-26 2020-03-04 Salk Institute for Biological Studies ONCOLYTIC HSV-1 VIRUS THERAPIES WITH SPECIFIC KILLING OF OLD-DEPENDENT CARCINOMAS
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
EP3856914A1 (en) 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CN113454105A (zh) 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
IL307350A (en) 2021-04-02 2023-11-01 Krystal Biotech Inc Viral vectors for cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162231A (en) * 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) * 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
CA2132976C (en) * 1992-03-31 2003-12-30 Bernard Roizman Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US20020010144A1 (en) * 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6406861B1 (en) * 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
EP1150696B1 (en) * 1999-02-05 2006-05-10 Arch Development Corporation Genetically engineered herpes virus for the treatment of tumours
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US7064111B1 (en) * 1999-10-05 2006-06-20 Georgetown University Use of soluble costimulatory factor for tumor immuno-gene therapy
US20020071832A1 (en) * 2000-06-01 2002-06-13 Yuman Fong Use of mutant herpes viruses and anticancer agents in the treatment of cancer
EP1381280B1 (en) * 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods

Similar Documents

Publication Publication Date Title
He et al. Cancer treatment evolution from traditional methods to stem cells and gene therapy
Serša et al. Electrochemotherapy: variable anti-tumor effect on different tumor models
Li et al. Cytokine and immuno-gene therapy for solid tumors
JP2017506662A5 (cg-RX-API-DMAC7.html)
KR102727195B1 (ko) 치료 백신으로서 사용되기 위한 나노입자
Yun et al. Convection‐Enhanced Delivery for Targeted Delivery of Antiglioma Agents: The Translational Experience
Naik et al. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?
Hou et al. Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L/Flt3L mRNA-mediated dendritic cell activation
Wang et al. Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors
CN116271054B (zh) 一种工程化髓样细胞及其制备方法和用途
Zhao et al. The role of mesenchymal stem cells in cancer immunotherapy
WO2010026638A1 (ja) 抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法
KR20070008710A (ko) 바이러스 및 캄토테신을 이용한 암치료 방법
Lan et al. Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy. Cells 2021, 10, 100
Hu et al. Natural anti-inflammatory and photothermal hydrogel alleviates cancer-related fatigue and motor/cognitive dysfunction
CN113117088A (zh) 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用
Hashimura et al. Gene therapy by in vivo interferon-gamma gene transfer to murine bladder tumor
Lu Evaluation of viral therapy for cancer treatment
WO2004087208A1 (ja) 熱ショックタンパク質と磁性微粒子からなる悪性腫瘍の温熱治療剤
Bossow et al. 832. Intrapleural Administration of Third Generation Oncolytic HSV-1 (G47∆) Is Highly Efficacious in Orthotopic Malignant Pleural Mesothelioma Models
Mccray et al. 948. Regression of Established Melanoma Tumors through Intratumoral Delivery of HIV-1 Vpr Using In Vivo Electroporation
Collichio et al. A phase 1b/2 multicenter, open-label trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) versus ipi alone in previously untreated, unresected, stage IIIB-IV melanoma
Tsuno et al. 480. STAT3-Inactivated Dendritic Cell Vaccination Could Induce Stronger Anti-Tumor Immune Responses
Bai et al. 947. RNAi-Mediated Bcl-XL Depletion Sensitizes Pancreatic Cancer Cells to TNF [alpha] Induced Apoptosis
CN117695242A (zh) 环二核苷酸自组装纳米粒子及其制备和应用